Zephyr AI Revolutionizes Precision Medicine with $111M Series A Funding
March 17, 2024, 2:21 pm
Zephyr AI, a healthcare technology company based in McLean, VA, has secured $111 million in Series A financing to advance its mission of democratizing precision medicine through explainable AI solutions. Backed by Revolution Growth, Eli Lilly & Company, Jeff Skoll, and EPIQ Capital Group, the company plans to enhance its analytical speed, expand its data sets, and accelerate the delivery of insights to the market.
Led by Grant Verstandig and Jeff Sherman, Zephyr AI is developing cutting-edge data federation tools and machine learning algorithms in the fields of oncology and cardiometabolic disease. By curating a comprehensive healthcare dataset and combining it with AI algorithms, the company aims to generate novel insights that support patients, providers, and ongoing research efforts.
With a focus on real-world patient data and biological context, Zephyr AI's technology goes beyond predictions to provide crucial insights for drug development and treatment decisions. By leveraging AI to extract novel insights and improve patient stratification, the company is poised to revolutionize precision medicine and enhance the success of clinical trials.
Through strategic partnerships and a world-class team, Zephyr AI is at the forefront of transforming the healthcare industry and improving outcomes for patients. With this latest round of funding, the company is well-positioned to drive innovation and make a lasting impact on the future of precision medicine.
Led by Grant Verstandig and Jeff Sherman, Zephyr AI is developing cutting-edge data federation tools and machine learning algorithms in the fields of oncology and cardiometabolic disease. By curating a comprehensive healthcare dataset and combining it with AI algorithms, the company aims to generate novel insights that support patients, providers, and ongoing research efforts.
With a focus on real-world patient data and biological context, Zephyr AI's technology goes beyond predictions to provide crucial insights for drug development and treatment decisions. By leveraging AI to extract novel insights and improve patient stratification, the company is poised to revolutionize precision medicine and enhance the success of clinical trials.
Through strategic partnerships and a world-class team, Zephyr AI is at the forefront of transforming the healthcare industry and improving outcomes for patients. With this latest round of funding, the company is well-positioned to drive innovation and make a lasting impact on the future of precision medicine.